Compare Incyte Corporation (INCY) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Remitly Global Inc — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.54B), while Remitly Global Inc trades at $23.73 (market cap $4.97B). The key difference: Incyte Corporation is far larger — about 4.9× Remitly Global Inc's market cap. Which is the better fit depends on your goals.
| INCY | RELY | |
|---|---|---|
Market Cap | $24.54B | $4.97B |
Sector | Health | Technology |
52-Week High | $129.93 | $25.93 |
52-Week Low | $81.61 | $12.20 |
Enterprise Value | $20.04B | $4.33B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
